NCT05576389View on ClinicalTrials.gov

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

December 31, 2026

Conditions
Germline BRCA-mutated HER2-negative Breast Cancer
Interventions
DRUG

Camrelizumab+Fluzoparib

Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle

Trial Locations (1)

100044

Breast Cancer, Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Jiangsu Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

lead

Peking University People's Hospital

OTHER